HRP20211823T1 - Anti-cd277 antitijela i njihove uporabe - Google Patents
Anti-cd277 antitijela i njihove uporabe Download PDFInfo
- Publication number
- HRP20211823T1 HRP20211823T1 HRP20211823TT HRP20211823T HRP20211823T1 HR P20211823 T1 HRP20211823 T1 HR P20211823T1 HR P20211823T T HRP20211823T T HR P20211823TT HR P20211823 T HRP20211823 T HR P20211823T HR P20211823 T1 HRP20211823 T1 HR P20211823T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- antibody
- use according
- cells
- costimulates
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000004940 costimulation Effects 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000000066 myeloid cell Anatomy 0.000 claims 1
- 201000005443 oral cavity cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fats And Perfumes (AREA)
Claims (8)
1. Anti-CD277 antitijelo za uporabu u terapiji, pri čemu navedeno antitijelo sadrži 6 CDR-ova antitijela mAb20.1 ili mAb7.2 koje se može dobiti iz hibridoma dostupnog pod CNCM depozitnim brojem 1-4401 ili 1-4402 odnosno, i
pri čemu navedeno anti-CD277 antitijelo aktivira citolitičku funkciju, proizvodnju citokina i proliferaciju Vγ9/Vδ2 T stanica.
2. Anti-CD277 antitijelo za uporabu prema zahtjevu 1, naznačeno time što navedeno anti-CD277 antitijelo
- kostimulira T stanice zajedno s CD3-TCR, i - kostimulira T stanice uz CD28-B7 kostimulaciju, i
- povećava aktivnost i/ili preživljavanje monocita i dendritskih stanica.
3. Anti-CD277 antitijelo za uporabu prema bilo kojem od gornjih zahtjeva, naznačeno time što je navedeno antitijelo monoklonsko, himerno ili humanizirano antitijelo.
4. Anti-CD277 antitijelo za uporabu prema zahtjevu 1 ili 2, naznačeno time što se navedeno anti-CD277 antitijelo može dobiti iz hibridoma dostupnog pod CNCM depozitnim brojem 1-4401 ili 1-4402.
5. Anti-CD277 antitijelo za uporabu prema bilo kojem od gornjih zahtjeva, naznačeno time što je navedena terapija rak.
6. Anti-CD277 antitijelo za uporabu prema zahtjevu 5, naznačeno time što je navedeni rak hematološki malignitet.
7. Anti-CD277 antitijelo za uporabu prema zahtjevu 6, naznačeno time što je hematološki malignitet neoplazma mijeloične stanične loze.
8. Anti-CD277 antitijelo za uporabu prema zahtjevu 5, naznačeno time što je navedeni rak nehematološki rak odabran iz skupine koju čine rak debelog crijeva, rak dojke, rak pluća, rak mozga, rak prostate, rak glave i vrata, rak gušterače, rak mokraćnog mjehura, kolorektalni rak, rak kostiju, rak vrata maternice, rak jetre, rak usne šupljine, rak jednjaka, rak štitnjače, rak bubrega, rak želuca, rak testisa i rak kože.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2010/003417 WO2012080769A1 (en) | 2010-12-15 | 2010-12-15 | Anti-cd277 antibodies and uses thereof |
EP15151003.9A EP2946791B1 (en) | 2010-12-15 | 2011-12-14 | Anti-CD277 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211823T1 true HRP20211823T1 (hr) | 2022-03-04 |
Family
ID=43828073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211823TT HRP20211823T1 (hr) | 2010-12-15 | 2011-12-14 | Anti-cd277 antitijela i njihove uporabe |
Country Status (13)
Country | Link |
---|---|
US (1) | US20140322235A1 (hr) |
EP (3) | EP2651441A1 (hr) |
JP (2) | JP6138693B2 (hr) |
CY (1) | CY1125057T1 (hr) |
ES (1) | ES2899733T3 (hr) |
HR (1) | HRP20211823T1 (hr) |
HU (1) | HUE057004T2 (hr) |
LT (1) | LT2946791T (hr) |
PL (1) | PL2946791T3 (hr) |
PT (1) | PT2946791T (hr) |
RS (1) | RS62700B1 (hr) |
SI (1) | SI2946791T1 (hr) |
WO (2) | WO2012080769A1 (hr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150353643A1 (en) * | 2013-09-24 | 2015-12-10 | Universite De La Mediterranee - Aix-Marseille Ii | Anti-cd277 antibodies and uses thereof |
EP3490675A4 (en) * | 2016-07-29 | 2020-07-29 | New York University | T GAMMA DELTA LYMPHOCYTES USED AS A TARGET FOR THE TREATMENT OF SOLID TUMORS |
WO2018082590A1 (zh) * | 2016-11-02 | 2018-05-11 | 北京蛋白质组研究中心 | 肿瘤免疫治疗靶标及其应用 |
US20200188482A1 (en) * | 2017-04-28 | 2020-06-18 | The Brigham And Women`S Hospital, Inc. | Targeting gamma-delta t cells in obesity and cachexia |
KR20200133323A (ko) | 2017-09-21 | 2020-11-27 | 임체크 테라퓨틱스 에스에이에스 | Btn2에 대해 특이성을 갖는 항체 및 이의 용도 |
US10519236B2 (en) | 2018-01-23 | 2019-12-31 | New York University | Antibodies specific to delta 1 chain of T cell receptor |
WO2019211370A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
WO2019211369A1 (en) * | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
IL280563B1 (en) | 2018-08-01 | 2024-06-01 | Imcheck Therapeutics Sas | Antibodies against BTN3A and their uses for the treatment of cancer and infectious diseases |
WO2020033926A2 (en) * | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antibodies that bind cd277 and uses thereof |
US20210388089A1 (en) * | 2018-08-09 | 2021-12-16 | Compass Therapeutics Llc | Antigen binding agents that bind cd277 and uses thereof |
WO2020033925A2 (en) * | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antibodies that bind cd277 and uses thereof |
AU2019406662A1 (en) * | 2018-12-18 | 2021-06-17 | Merck Sharp & Dohme Llc | Methods of using butyrophilin antibodies for treating HIV infection |
CN113412281B (zh) * | 2018-12-26 | 2024-07-23 | 感应检查疗法公司 | Btn3a结合蛋白及其用途 |
CA3134122A1 (en) | 2019-03-20 | 2020-09-24 | Imcheck Therapeutics Sas | Antibodies having specificity for btn2 and uses thereof |
CN117295505A (zh) * | 2021-02-08 | 2023-12-26 | 加利福尼亚大学董事会 | 嗜乳脂蛋白亚家族3成员a1(btn3a1,cd277)的调节 |
TW202313695A (zh) | 2021-09-15 | 2023-04-01 | 法商感應檢查療法公司 | 抗btn3a抗體在製備用於治療腫瘤的藥物的用途 |
WO2023052541A1 (en) | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy |
IL312118A (en) | 2021-10-27 | 2024-06-01 | Imcheck Therapeutics | Butyrophilin (BTN) A3-activating antibodies for use in infectious disease treatment methods |
WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
TW202400638A (zh) | 2022-05-10 | 2024-01-01 | 法商感應檢查療法公司 | 用於治療胃腸發炎病症之方法的抗btn3a抗體 |
WO2024074498A1 (en) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP0689601B1 (en) | 1993-02-22 | 2006-10-04 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
KR100261941B1 (ko) | 1994-07-13 | 2000-07-15 | 나가야마 오사무 | 사람의 인터루킨-8에 대한 재구성 사람항체 |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
AU690474B2 (en) | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
JP2001522241A (ja) | 1997-04-10 | 2001-11-13 | ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ | 診断方法および試薬 |
-
2010
- 2010-12-15 WO PCT/IB2010/003417 patent/WO2012080769A1/en active Application Filing
-
2011
- 2011-12-14 EP EP11802346.4A patent/EP2651441A1/en not_active Withdrawn
- 2011-12-14 HR HRP20211823TT patent/HRP20211823T1/hr unknown
- 2011-12-14 JP JP2013543767A patent/JP6138693B2/ja not_active Expired - Fee Related
- 2011-12-14 HU HUE15151003A patent/HUE057004T2/hu unknown
- 2011-12-14 PT PT151510039T patent/PT2946791T/pt unknown
- 2011-12-14 SI SI201132018T patent/SI2946791T1/sl unknown
- 2011-12-14 EP EP21182452.9A patent/EP3915582A3/en active Pending
- 2011-12-14 RS RS20211469A patent/RS62700B1/sr unknown
- 2011-12-14 WO PCT/EP2011/072787 patent/WO2012080351A1/en active Application Filing
- 2011-12-14 US US13/994,277 patent/US20140322235A1/en not_active Abandoned
- 2011-12-14 PL PL15151003T patent/PL2946791T3/pl unknown
- 2011-12-14 LT LTEP15151003.9T patent/LT2946791T/lt unknown
- 2011-12-14 ES ES15151003T patent/ES2899733T3/es active Active
- 2011-12-14 EP EP15151003.9A patent/EP2946791B1/en active Active
-
2016
- 2016-11-04 JP JP2016216470A patent/JP6408534B2/ja active Active
-
2021
- 2021-12-01 CY CY20211101047T patent/CY1125057T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2012080769A1 (en) | 2012-06-21 |
EP3915582A2 (en) | 2021-12-01 |
SI2946791T1 (sl) | 2022-02-28 |
PL2946791T3 (pl) | 2022-02-21 |
WO2012080351A1 (en) | 2012-06-21 |
PT2946791T (pt) | 2021-12-07 |
JP2014503522A (ja) | 2014-02-13 |
JP6408534B2 (ja) | 2018-10-17 |
EP2946791B1 (en) | 2021-09-08 |
EP3915582A3 (en) | 2021-12-08 |
JP6138693B2 (ja) | 2017-05-31 |
LT2946791T (lt) | 2022-01-10 |
JP2017061502A (ja) | 2017-03-30 |
US20140322235A1 (en) | 2014-10-30 |
EP2651441A1 (en) | 2013-10-23 |
CY1125057T1 (el) | 2023-06-09 |
ES2899733T3 (es) | 2022-03-14 |
HUE057004T2 (hu) | 2022-04-28 |
EP2946791A1 (en) | 2015-11-25 |
RS62700B1 (sr) | 2022-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211823T1 (hr) | Anti-cd277 antitijela i njihove uporabe | |
NZ616405A (en) | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors | |
HRP20171653T1 (hr) | Vezna sredstva koja služe ciljano protiv b7-h1 | |
HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
MX2021013336A (es) | Anticuerpos y receptores de antigeno quimericos especificos para cd19. | |
HRP20161736T1 (hr) | Protutijelo koje prepoznaje čimbenik inhibicije ljudske leukemije (lif) i upotreba protutijela protiv lif u liječenju bolesti povezanih s nepoželjnom staničnom proliferacijom | |
EP4316596A3 (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer | |
JP2018512443A5 (hr) | ||
MX2020009463A (es) | Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor. | |
PH12015502439A1 (en) | Anti-cd38 antibodies and fusions to attenuated inferferon alpha-2b | |
MX2020001224A (es) | Anticuerpos para el tratamiento del cancer. | |
MY187624A (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor | |
WO2012127464A3 (en) | Constitutively activated t cells for use in adoptive cell therapy | |
RU2016107884A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
NZ604007A (en) | Monoclonal antibodies against her2 epitope | |
TN2012000437A1 (en) | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof | |
IN2014DN06522A (hr) | ||
RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
MX353813B (es) | Moleculas de union a vegf. | |
MX347320B (es) | Anticuerpo bloqueador de agr2 y uso del mismo. | |
PH12014500679A1 (en) | Chimeric and humanized anti-cd44 antibodies that mediate cancer cell cytotoxicity | |
JP2015530989A5 (hr) | ||
WO2016022939A8 (en) | Human monoclonal antibodies specific for 5t4 and methods of their use | |
RU2015108797A (ru) | Антитела к jagged и способы их применения перекрестная ссылка на родственные заявки | |
TN2011000417A1 (en) | Humanised antibodies with anti-tumour activity |